Cannabis Science Signs A New Non-Exclusive Commercial License Agreement with Rockbrook To Continue Its Strategic Partnership In The State Of Colorado
COLORADO SPRINGS, Colo., Jul 12, 2011 (BUSINESS WIRE) -- Cannabis Science Inc. (NASD OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to update its shareholders that over the last month, Cannabis Science, Rockbrook and Mr. Adam Pasquale, its principal, have now signed a new non-exclusive commercial licensing agreement ("CLA") and agreed to map out a plan to continue a mutually beneficial strategic partnership within the State of Colorado. Under the new agreement, Rockbrook will develop and distribute Cannabis Science's proprietary medical cannabis delivery methods and formulations in the State of Colorado on a case by case basis.
The new agreement with Rockbrook will permit Cannabis Science to move forward expanding its licensing and product delivery capacity inside and outside of Colorado through new partnerships and license agreements to maximize market potential for the Company and shareholders.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "The new commercial license agreement with Rockbrook will continue to benefit both parties and we will continue to delivery our proprietary medical cannabis products and delivery methods through Rockbrook on a case by case basis. Rockbrook will also continue to share critical patient data with Cannabis Science to further our studies and product development." |
